International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494

Nanoemulsion-Based Drug Delivery Systems: Advances and Applications for Poorly Water-Soluble Drugs

Mr. Chetan Vijaykumar Jain[1]*, Dr. Jagtap Vaibhavkumar Arun[2]
[1] *DCS's A.R.A College of Pharmacy, Nagaon, Dhule.*
[2]*NES's Gangamai College of Pharmacy, Nagaon, Dhule.*

Date of Submission: 15-08-2025 Date of Acceptance: 25-08-2025

ABSTRACT
Poorly water-soluble drugs pose significant challenges in pharmaceutical development due to their limited aqueous solubility, which often results in low bioavailability and suboptimal therapeutic efficacy. Nanoemulsion-based drug delivery systems have gained considerable attention as a promising strategy to address these limitations. Nanoemulsions, characterized by their nanoscale droplet size and enhanced kinetic stability, offer improved solubilization, protection of labile drugs, and potential for controlled and targeted delivery. This review provides a comprehensive overview of the fundamentals, formulation approaches, preparation techniques, and characterization methods of nanoemulsions. It also highlights recent applications in delivering poorly water-soluble drugs across various administration routes, along with an analysis of current challenges and future innovations. The discussion underscores the critical role of nanoemulsions in enhancing drug bioavailability and therapeutic outcomes, paving the way for their successful clinical translation and commercial use.

KEY WORDS: Nanoemulsions, Poorly water-soluble drugs, Drug delivery systems, Bioavailability enhancement, Nanotechnology, Formulation strategies, Controlled release, Targeted delivery, Pharmaceutical nanocarriers, Drug solubilization.

I. INTRODUCTION

The formulation and delivery of poorly water-soluble drugs represent a critical challenge in pharmaceutical sciences, as approximately 40% to 70% of newly developed drugs suffer from inadequate aqueous solubility, leading to poor bioavailability and suboptimal therapeutic efficacy (Lipinski, 2000; Savjani, Gajjar, & Savjani, 2012). Poor solubility can significantly limit oral absorption, often resulting in low and erratic plasma drug concentrations, which complicate dose optimization and compromise patient outcomes (Kesisoglou, Panmai, & Wu, 2007).

Conventional formulation strategies, such as salt formation, particle size reduction, solid dispersions, and use of surfactants or co-solvents, have been utilized to address solubility issues (Serajuddin, 2007; Patel, Amiji, & Chaubal, 2011). However, these approaches sometimes face limitations, including instability during storage, lack of scalability, and potential toxicity due to excipients or solvents employed (Patel et al., 2011). Therefore, innovative and efficient drug delivery platforms are highly sought to overcome these barriers.

Nanotechnology-based delivery systems have emerged as promising solutions, offering enhanced solubilization, protection of labile drugs, and improved bioavailability (Singh & Lillard, 2009). Among these, nanoemulsions—a class of kinetically stable, submicron oil-in-water or water-in-oil dispersions stabilized by surfactants—have gained considerable attention due to their ease of preparation, excellent physical stability, and ability to incorporate hydrophobic drugs (Solans & Kunieda, 2011; Shakeel et al., 2008).

Nanoemulsions typically exhibit droplet sizes between 20 and 200 nanometers, which results in a large interfacial surface area, enhancing drug solubilization and absorption (Muller, Keck, & Mehnert, 2011). This size range also facilitates enhanced permeation across biological membranes and potential lymphatic uptake, bypassing hepatic first-pass metabolism and improving systemic drug availability (Porter, Trevaskis, & Charman, 2007). Furthermore, nanoemulsions provide the flexibility for various routes of administration, including oral, topical, parenteral, and ocular delivery, expanding their therapeutic applicability (Date, Nagarsenker, & Devarajan, 2010).

The formulation of nanoemulsions requires careful selection of oils, surfactants, and co-surfactants to ensure drug solubilization, physical stability, and biocompatibility. Various preparation methods, such as high-pressure homogenization, ultrasonication, and phase inversion techniques, enable fine-tuning of droplet

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494

size and stability to meet specific therapeutic goals (Shakeel et al., 2008; Solans & Kunieda, 2011).

Recent years have witnessed a surge in research focusing on nanoemulsions for delivery of poorly water-soluble drugs like paclitaxel, curcumin, coenzyme Q10, and many others, demonstrating improved pharmacokinetics, enhanced therapeutic effects, and reduced side effects (Patel et al., 2011; Date et al., 2010). However, challenges such as long-term physical stability, scale-up manufacturing, and regulatory approval remain to be fully addressed (Muller et al., 2011).

This review aims to provide a comprehensive overview of the advances in nanoemulsion-based drug delivery systems, discussing fundamental concepts, formulation strategies, characterization techniques, and therapeutic applications for poorly water-soluble drugs. Additionally, current challenges and future perspectives toward clinical translation are explored.

Table 1:Classification of Poorly Water-Soluble Drugs and Their Challenges.

Classification System	Class/Category	Description	Examples	Challenges in Formulation/Delivery
BCS (Biopharmaceutics Classification System)	Class II	Poor solubility, high permeability	Ketoconazole, Carbamazepine	Low bioavailability due to poor dissolution rate
	Class IV	Poor solubility, poor permeability	Hydrochlorothiazide, Nevirapine	Very low absorption; formulation challenging due to dual issues
Solubility-based classification	Practically Insoluble	Solubility < 0.1 mg/mL	Griseofulvin, Phenytoin	Difficult to dissolve, leading to poor absorption
	Sparingly Soluble	Solubility 0.1 - 1 mg/mL	Ibuprofen, Naproxen	Requires solubilization techniques; may precipitate in GI tract
BCS Class II Subtypes	Weakly Acidic Drugs	Solubility varies with pH; better solubility in intestinal pH	Ibuprofen, Ketoprofen	Variable dissolution; pH-dependent solubility challenges
	Weakly Basic Drugs	Solubility decreases in alkaline pH	Ritonavir, Nifedipine	Precipitation risk in intestines; bioavailability reduction
Lipid Solubility / Lipophilicity	Highly Lipophilic Drugs	High log P value, low aqueous solubility	Paclitaxel, Cyclosporine	Requires lipid-based formulations; poor aqueous dispersion
Physicochemical Properties	High Molecular Weight Drugs	Often low solubility due to size		



Figure 1: Schematic Representation of Nanoemulsion Structure

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494

II. FUNDAMENTALS OF NANOEMULSIONS

2.1. Definition and Characteristics of Nanoemulsions

Nanoemulsions are thermodynamically unstable but kinetically stable colloidal dispersions consisting of two immiscible liquids (oil and water) stabilized by an interfacial film of surfactants, with droplet sizes typically ranging from 20 to 200 nanometers (Solans & Kunieda, 2011). Due to their small droplet size, nanoemulsions possess unique physicochemical properties, including high surface area, optical transparency or translucency, and enhanced stability against sedimentation, creaming, and coalescence compared to conventional emulsions (Mason, Wilking, Meleson, Chang, & Graves, 2006).

Key characteristics of nanoemulsions include:

- **Droplet size:** Typically 20–200 nm, much smaller than conventional emulsions (0.2–20 μm), leading to a large interfacial surface area that improves drug solubilization and absorption (Shakeel et al., 2008).
- **Kinetic stability:** Although thermodynamically unstable, nanoemulsions remain stable for long periods due to the small droplet size and surfactant stabilization preventing droplet aggregation (Jaiswal, Dudhe, & Sharma, 2015).
- **Appearance:** Nanoemulsions are often translucent or slightly opalescent, unlike milky conventional emulsions, due to light scattering properties of nanodroplets smaller than the wavelength of visible light (Anton, Vandamme, & Vasseur, 2008).
- **Lowviscosity:** Compared to gels or microemulsions, nanoemulsions generally have low viscosity, facilitating easy application and absorption (Date et al., 2010).

2.2. Types of Nanoemulsions

Nanoemulsions can be classified based on the dispersed and continuous phases:

i. Oil-in-Water (O/W) Nanoemulsions:

The oil droplets are dispersed in a continuous aqueous phase. This type is most common for delivering hydrophobic drugs orally or topically due to easy compatibility with the body's aqueous environment (Solans & Kunieda, 2011).

ii. Water-in-Oil (W/O) Nanoemulsions:

Water droplets are dispersed within a continuous oil phase. These are less common but useful in applications such as topical formulations and controlled release systems (Mason et al., 2006).

iii. Bi-continuous Nanoemulsions:

Both oil and water phases form interpenetrating continuous networks stabilized by surfactants. This complex structure is less common but can allow controlled release and unique solubilization profiles (Jaiswal et al., 2015).

2.3. Methods of Preparation

Nanoemulsions can be prepared by two broad categories of techniques:

i. High-Energy Methods

These methods use mechanical devices to apply intense disruptive forces to break down coarse emulsions into nano-sized droplets.

- **High-Pressure Homogenization:** The emulsion is forced through a narrow gap at very high pressures (up to 2000 bar), producing intense turbulence and cavitation that reduce droplet size (Jaiswal et al., 2015).



Figure 2: Schematic of High-Pressure Homogenization Process

- **Ultrasonication:** High-frequency ultrasound waves create cavitation bubbles that collapse, breaking droplets into nanoscale sizes (Shakeel et al., 2008).

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494



Figure 3:Ultrasonication Setup and Cavitation Mechanism

- **Microfluidization:** Fluid streams are forced through microchannels under high pressure, creating shear and impact forces that form nanoemulsions (Anton et al., 2008).



Figure 4: Microfluidization process for the preparation of nanodelivery systems.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494

These methods generally produce narrow size distribution nanoemulsions with high stability but require expensive equipment and high energy input.

ii. Low-Energy Methods

These methods exploit physicochemical properties of components and spontaneous emulsification phenomena without requiring high mechanical energy.

- **Phase Inversion Temperature (PIT):** Based on temperature-dependent changes in surfactant affinity, the system passes through a phase inversion point where droplet size minimizes, forming nanoemulsions (Solans & Kunieda, 2011).



Figure 5: Phase Inversion Temperature (PIT) Method Diagram

- **Spontaneous Emulsification:** When an organic phase containing oil and surfactants is added to the aqueous phase under gentle stirring, spontaneous formation of nano-sized droplets occurs due to diffusion and interfacial turbulence (Date et al., 2010).

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494



Figure 6: Spontaneous Emulsification Mechanism

- **Self-Nanoemulsifying Drug Delivery Systems (SNEDDS):** Formulations comprising oils, surfactants, and co-surfactants that spontaneously form nanoemulsions upon dilution in gastrointestinal fluids (Porter, Trevaskis, & Charman, 2007).



Figure 7: Self-Nanoemulsifying Drug Delivery Systems (SNEDDS)

Low-energy methods are often more scalable, energy-efficient, and suitable for heat-sensitive drugs but may require specific formulation optimization.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494



Figure 8: Flowchart of Nanoemulsion Preparation Techniques

Table 2: Common Oils, Surfactants, and Co-surfactants for Nanoemulsions

Component Type	Examples	Key Properties	Role in Nanoemulsion
Oils	Medium-chain triglycerides (MCT), Olive oil, Castor oil, Isopropyl myristate	Solubilize lipophilic drugs; viscosity and polarity affect droplet size	Oil phase to dissolve drug and form droplets
Surfactants	Tween 80, Span 80, Cremophor EL, Poloxamer 188	Nonionic, ionic; HLB values guide selection; reduce interfacial tension	Stabilize oil-water interface, reduce droplet size
Co-surfactants	Ethanol, Propylene glycol, PEG 400, Butanol	Increase interfacial film fluidity; reduce surfactant concentration	Assist surfactants; improve stability and droplet formation

Table 3: Comparison of Emulsifiers and Stabilizers

Agent Type	Common Examples	Mechanism of Action	Advantages	Limitations
Emulsifiers	Tween 80, Span 80	Reduce interfacial tension; adsorb at oil-water interface	Enhance droplet formation and stability	Potential toxicity at high conc.
Stabilizers	PEG, Gums (e.g., xanthan)	Increase viscosity; provide steric hindrance to prevent coalescence	Improve long-term physical stability	May affect viscosity or drug release

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494

Table 4: Factors Affecting Stability and Drug Loading in Nanoemulsions

Factor	Effect on Stability	Effect on Drug Loading	Notes
Droplet size and uniformity	Smaller, uniform droplets improve kinetic stability	Smaller droplets may limit drug capacity	Optimized by surfactant concentration
Surfactant concentration	Adequate coverage prevents coalescence	Excess surfactant may solubilize drug	Balance to reduce toxicity
Oil phase type	Oil polarity affects Ostwald ripening	Determines solubility and loading of drug	Select oil with high drug affinity
Temperature & pH	Extreme conditions destabilize droplets	Can degrade drug or excipients	Important for storage and formulation
Drug properties	Solubility and chemical stability affect loading	Poorly soluble drugs benefit most	Drug-excipient compatibility crucial

III. ADVANTAGES OF NANOEMULSION-BASED DRUG DELIVERY

3.1. Enhanced Solubility and Dissolution Rate

Nanoemulsions significantly enhance the solubility and dissolution rate of poorly water-soluble drugs by increasing the surface area available for drug release. The nanoscale droplets, typically 20–200 nm in diameter, provide a large interfacial area between the oil and aqueous phases, improving drug dispersion and solubilization (Shakeel et al., 2008). This results in faster dissolution rates compared to conventional formulations, which is critical for drugs with low aqueous solubility and limited bioavailability (Kesisoglou, Panmai, & Wu, 2007).

Additionally, the oil phase in nanoemulsions acts as a solubilizing reservoir, maintaining the drug in a dissolved state and preventing precipitation upon dilution in the gastrointestinal tract (Date, Nagarsenker, & Devarajan, 2010).

3.2. Improved Bioavailability and Therapeutic Efficacy

By enhancing solubility and dissolution, nanoemulsions improve oral bioavailability of lipophilic drugs, which often suffer from poor absorption and first-pass metabolism (Porter, Trevaskis, & Charman, 2007). The small droplet size facilitates rapid and more complete absorption across the gastrointestinal mucosa due to increased membrane contact and possible uptake via lymphatic transport pathways, bypassing hepatic metabolism (Singh & Lillard, 2009).

Clinical studies have demonstrated increased plasma concentrations and improved therapeutic outcomes for drugs such as paclitaxel and curcumin when delivered via nanoemulsion systems (Date et al., 2010). This improved bioavailability translates to enhanced efficacy at lower doses and reduced systemic toxicity.

3.3. Protection of Labile Drugs from Degradation

Nanoemulsions provide a protective environment for chemically or enzymatically labile drugs by encapsulating them within the oil droplets, thereby shielding them from harsh gastrointestinal conditions, enzymatic degradation, and oxidation (Shakeel et al., 2008). This protection enhances the stability and shelf life of sensitive drugs, improving their therapeutic reliability.

For example, drugs susceptible to hydrolysis or photodegradation have shown improved stability in nanoemulsion formulations, leading to sustained therapeutic effects (Date et al., 2010).

3.4. Controlled and Targeted Drug Delivery Potential

Nanoemulsions offer potential for controlled release and targeted delivery by modifying the composition of oils, surfactants, and the addition of ligands or stimuli-responsive agents (Muller, Keck, & Mehnert, 2011). The small droplet size and surface properties allow for passive targeting via enhanced permeability and retention (EPR) effects in tumor tissues or active targeting through ligand conjugation (Singh & Lillard, 2009).

Moreover, nanoemulsions can be engineered for specific routes of administration, including topical, ocular, and parenteral, allowing localized drug release with minimized systemic side effects (Date et al., 2010).

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494

IV. FORMULATION COMPONENTS AND CONSIDERATIONS

4.1. Selection of Oils, Surfactants, and Co-surfactants

The choice of formulation components is critical in developing stable nanoemulsions with high drug-loading capacity and optimal performance.

- **Oils**: The oil phase solubilizes the poorly water-soluble drug and influences droplet size, stability, and release profile. Natural (e.g., olive oil, castor oil) and synthetic oils (e.g., medium-chain triglycerides, isopropyl myristate) are commonly used (Date, Nagarsenker, & Devarajan, 2010). Oils with good solubilization capacity for the drug and suitable viscosity are preferred for efficient nanoemulsion formation and stability (Shakeel et al., 2008).
- **Surfactants**: Surfactants lower the interfacial tension between oil and water phases, facilitating droplet formation and stability. Nonionic surfactants such as Tween 80, Span 80, and Cremophor EL are favored due to their low toxicity and good emulsifying properties (Jaiswal, Dudhe, & Sharma, 2015). The hydrophilic-lipophilic balance (HLB) of surfactants guides their selection; high HLB surfactants (>10) are typically used for oil-in-water nanoemulsions.
- **Co-surfactants**: These are often short-chain alcohols or polyethylene glycol derivatives (e.g., ethanol, propylene glycol) that increase the fluidity of the interfacial film, reduce surfactant concentration needed, and improve nanoemulsion stability (Solans & Kunieda, 2011). Co-surfactants help reduce droplet size and stabilize the system against coalescence.

4.2. Role of Emulsifiers and Stabilizers

- **Emulsifiers** are surface-active agents that adsorb at the oil-water interface, reducing interfacial tension and forming a protective layer around droplets to prevent coalescence (Anton, Vandamme, & Vasseur, 2008).
- **Stabilizers** (e.g., polymers like polyethylene glycol or natural gums) can increase viscosity and provide steric stabilization to droplets, improving physical stability and preventing phase separation (Muller, Keck, & Mehnert, 2011).

The right combination and concentration of emulsifiers and stabilizers are essential for producing kinetically stable nanoemulsions with desirable shelf life.

4.3. Factors Affecting Stability and Drug Loading

- **Droplet size and size distribution**: Smaller and more uniform droplets enhance kinetic stability by reducing creaming and sedimentation (Jaiswal et al., 2015).
- **Surfactant concentration**: Adequate surfactant concentration ensures full coverage of droplets; too low levels cause coalescence, while too high levels may lead to toxicity (Shakeel et al., 2008).
- **Oil phase properties**: The type and amount of oil influence drug solubility and partitioning, affecting loading capacity and release kinetics (Date et al., 2010).
- **Temperature and pH**: Environmental conditions can impact the integrity of the interfacial film and overall nanoemulsion stability (Solans & Kunieda, 2011).
- **Drug properties**: Drug solubility, molecular weight, and chemical stability determine the amount that can be loaded and maintained within the nanoemulsion system (Porter, Trevaskis, & Charman, 2007).

V. TECHNIQUES FOR NANOEMULSION PREPARATION

5.1. High-Pressure Homogenization

This high-energy technique forces the coarse emulsion through a narrow valve at pressures of 100–2000 bar, producing intense turbulence, cavitation, and shear forces that break droplets into nanometer sizes (Jaiswal et al., 2015). It is widely used industrially due to scalability and reproducibility.

5.2. Ultrasonication

Ultrasonication applies high-frequency sound waves to generate cavitation bubbles in the liquid, which collapse and provide disruptive forces that reduce droplet size (Shakeel et al., 2008). It is suitable for lab-scale preparations but may cause localized heating and is less scalable.

5.3. Phase Inversion Temperature (PIT) Method

PIT exploits temperature-dependent changes in surfactant affinity (hydrophilic-lipophilic balance) to induce phase inversion from oil-in-water to water-in-oil or vice versa. At the inversion temperature, interfacial tension is minimal, facilitating formation of very small

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494

droplets (Solans & Kunieda, 2011). This low-energy technique is gentle and suitable for heat-sensitive compounds.

5.4. Spontaneous Emulsification

Also known as self-emulsification, this low-energy method involves mixing a solution of oil, surfactant, and co-surfactant in an organic solvent with an aqueous phase under gentle stirring. The diffusion of solvent into water and interfacial turbulence cause spontaneous formation of nano-sized droplets (Date et al., 2010). It is simple, cost-effective, and scalable.

VI. CHARACTERIZATION OF NANOEMULSIONS

Characterization is essential for ensuring that nanoemulsions meet the desired specifications for stability, drug delivery efficiency, and therapeutic performance. Key characterization parameters include:

6.1. Particle Size and Distribution

- **Definition**: Particle size influences solubility, bioavailability, and stability.
- **Measurement**: Dynamic Light Scattering (DLS) and Laser Diffraction are most commonly used.
- **Relevance**: Smaller particle sizes (typically 20–200 nm) enhance surface area, dissolution rate, and absorption.
- **Reference**: Shakeel, F., et al. (2012) report that optimal nanoemulsion droplet size can significantly improve oral absorption of hydrophobic drugs.

6.2. Zeta Potential

- **Definition**: An indicator of surface charge, influencing electrostatic stability.
- **Threshold**: ±30 mV is often considered adequate for physical stability.
- **Measurement**: Electrophoretic light scattering.
- **Reference**: Tadros, T., et al. (2004) highlight that high absolute zeta potential prevents droplet aggregation.

6.3. Morphology (Microscopy)

- **Techniques**: Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM), Atomic Force Microscopy (AFM).
- **Purpose**: To confirm droplet shape (spherical) and distribution.
- **Reference**: Solans, C., et al. (2005) demonstrate TEM use in confirming monodisperse spherical droplets in oil-in-water nanoemulsions.

6.4. Drug Encapsulation Efficiency (EE%) and Loading

- **Definition**: EE% is the percentage of the initial drug encapsulated within droplets; Drug Loading is the amount of drug per unit formulation.
- **Method**: Centrifugation/ultrafiltration followed by HPLC analysis.
- **Reference**: Kotta, S., et al. (2012) show that high EE% is crucial for sustained release and therapeutic efficiency.

6.5. Stability Studies

- **Types**:
- **Physical**: Centrifugation, freeze-thaw cycles, and storage at varying temperatures.
- **Chemical**: Drug degradation profile under light, oxygen, and pH changes.
- **Reference**: Lawrence, M. J., & Rees, G. D. (2012) suggest stability testing under ICH guidelines for shelf-life prediction.

Table 5: Summary of Nanoemulsion Characterization Parameters

Parameter	Method	Typical Values/Range	Importance
Particle size	Dynamic Light Scattering (DLS)	20–200 nm	Influences solubility, absorption
Polydispersity Index (PDI)	DLS	<0.3 (monodisperse)	Indicates size distribution uniformity
Zeta potential	Electrophoretic light scattering	±30 mV or higher	Electrostatic stability of droplets
Morphology	TEM, SEM, AFM	Spherical shape	Confirms droplet shape and size
Encapsulation Efficiency	Centrifugation + HPLC	Typically >70%	Drug loading and sustained delivery
Stability tests	Centrifugation, freeze-thaw, storage	No phase separation or size increase	Predict shelf-life and physical integrity

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494

VII. APPLICATIONS IN DELIVERING POORLY WATER-SOLUBLE DRUGS

Nanoemulsions are especially beneficial for drugs with poor aqueous solubility (BCS Class II and IV). They improve dissolution, absorption, and bioavailability.

7.1. Examples of Drugs Formulated as Nanoemulsions

- **Curcumin**: Enhanced bioavailability by >9-fold in oral formulations (Kumar, A., et al., 2016).
- **Paclitaxel**: Intravenous nanoemulsion avoided Cremophor EL toxicity and improved antitumor efficacy (Zhang, X., et al., 2015).
- **Coenzyme** Q10: Nanoemulsion improved plasma concentration and antioxidant activity (Ganesan, P., et al., 2017).

Table 6: Examples of Poorly Water-Soluble Drugs Delivered via Nanoemulsions

Drug	Indication	Route of Administration	Benefits Observed	Reference
Curcumin	Anti-inflammatory	Oral	9-fold bioavailability increase	Kumar et al., 2016
Paclitaxel	Cancer chemotherapy	Parenteral (IV)	Reduced toxicity, improved efficacy	Zhang et al., 2015
Coenzyme Q10	Antioxidant	Oral	Enhanced plasma concentration	Ganesan et al., 2017
Cyclosporine	Immunosuppressant	Oral	2.5 times improved bioavailability	Muller et al., 2000
Vitamin E	Antioxidant	Oral/Topical	Improved antioxidant activity	Ganesan et al., 2017

7.2. Routes of Administration

- **Oral**: Solubilization in the GI tract (e.g., curcumin nanoemulsions for inflammation).
- **Topical**: Enhanced skin penetration for antifungal and anti-inflammatory drugs.
- **Parenteral**: Rapid systemic delivery for chemotherapeutics and anesthetics.
- **Pulmonary**/Nasal: Targeted delivery for CNS drugs and vaccines.



Figure 9: Diagram of Routes of Administration for Nanoemulsions

7.3. Case Studies

- **Case 1**: Oral nanoemulsion of cyclosporine improved bioavailability by ~2.5 times compared to conventional formulations (Muller, R. H., et al., 2000).
- **Case 2**: Paclitaxel nanoemulsion demonstrated improved tumor suppression and reduced hypersensitivity (Zhang et al., 2015).
- **Case 3**: Vitamin E nanoemulsion improved antioxidant activity and reduced oxidative stress markers in vivo (Ganesan et al., 2017).

VIII. CHALLENGES AND LIMITATIONS OF NANOEMULSION DRUG DELIVERY SYSTEMS

8.1. Physical and Chemical Stability Issues

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494

Nanoemulsions are thermodynamically unstable systems that rely on kinetic stability for their shelf life. Major physical instability phenomena include:

- **Coalescence**: Fusion of droplets leading to phase separation.
- **OstwaldRipening**: Smaller droplets dissolve and redeposit onto larger droplets, increasing average droplet size over time, often due to solubility differences in the oil phase (Kotta et al., 2012).
- **Flocculation and Creaming**: Aggregation of droplets and upward movement due to density differences, impacting homogeneity.

Chemical instability may result from:

- Oxidation of unsaturated oils or drug molecules, especially in presence of light and oxygen (Shakeel et al., 2008).
- Hydrolysis or degradation of labile drugs within the formulation.
- Interaction of surfactants and co-surfactants with drugs leading to altered drug release or chemical changes.

Effective stabilization strategies such as using antioxidants, selecting oils less prone to oxidation, and optimizing surfactant systems are necessary to overcome these issues (Solans & Kunieda, 2011).

8.2. Scale-up and Manufacturing Challenges

While high-pressure homogenization and ultrasonication are effective for lab and pilot-scale production, translating these processes to industrial scale involves:

- Maintaining consistent droplet size distribution and physical stability across large batches.
- Controlling temperature to avoid degradation during high-energy processing.
- Ensuring reproducibility despite variations in raw material batches.
- Managing energy consumption and cost-effectiveness (Anton et al., 2008).

Continuous manufacturing processes and advanced inline monitoring tools are being explored to address scale-up hurdles.

8.3. Toxicity and Regulatory Issues

- Surfactants and co-surfactants, although essential for stability, may cause irritation, immunogenicity, or toxicity, particularly with long-term use or parenteral administration (Shakeel et al., 2008).
- Regulatory bodies require comprehensive toxicity profiling, including genotoxicity, cytotoxicity, and immunotoxicity assessments.
- The lack of standardized regulatory guidelines specific to nanoemulsions creates challenges for approval and commercialization.
-

8.4. Drug Loading and Release Control

- Nanoemulsions typically excel in delivering lipophilic drugs; however, hydrophilic drug encapsulation is limited due to their poor solubility in the oil phase (Date et al., 2010).
- Achieving controlled or sustained release can be difficult because nanoemulsions often release the drug rapidly upon dilution in physiological fluids.
- Hybrid systems combining nanoemulsions with polymers or liposomes are being investigated to improve release control.

Table 7: Challenges and Limitations of Nanoemulsions

Challenge	Description	Impact	Possible Solutions
Physical instability	Coalescence, Ostwald ripening, phase separation	Loss of efficacy and appearance	Optimized surfactants, antioxidants
Chemical degradation	Oxidation, hydrolysis of drugs/excipients	Reduced drug potency	Use of antioxidants, proper storage
Scale-up difficulties	Maintaining batch consistency and stability	Production costs and reproducibility	Continuous manufacturing processes
Toxicity concerns	Surfactants and excipients toxicity	Safety issues, especially parenteral	Use biocompatible ingredients
Limited drug loading	Poor encapsulation of hydrophilic drugs	Reduced therapeutic payload	Hybrid delivery systems
Controlled release challenges	Rapid drug release after administration	Suboptimal therapy	Polymer coatings or multi-layer systems

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494

Table 8: Strategies to Overcome Stability and Scale-up Challenges

Challenge	Strategy	Description	Examples/Notes
Physical instability	Use of mixed surfactant systems	Combine surfactants with complementary HLB values	Tween/Span blends
	Addition of antioxidants	Prevent oxidative degradation	Vitamin E, BHT
	Optimizing oil phase	Select oils less prone to Ostwald ripening	MCT oils
Scale-up issues	Process parameter control	Maintain pressure, temperature in homogenizers	Inline monitoring tools
	Continuous manufacturing	Employ scalable, controlled processes	Microfluidization
Toxicity concerns	Use biocompatible surfactants	Prefer nonionic, FDA-approved surfactants	Poloxamers, lecithin
Drug loading limitations	Hybrid nanoemulsions with polymers	Combine nanoemulsions with polymeric carriers	Nanoemulsion-liposome hybrids

IX. FUTURE PERSPECTIVES AND INNOVATIONS

9.1. Smart and Stimuli-Responsive Nanoemulsions

Emerging nanoemulsions respond to specific internal (pH, redox, enzymes) or external (temperature, magnetic fields) stimuli for site-specific drug release (Muller & Keck, 2011). For example:

- pH-responsive nanoemulsions release drugs preferentially in acidic tumor microenvironments or inflamed tissues.
- Thermo-responsive systems change their stability or release profiles in response to body temperature or externally applied heat.

9.2. Targeted Drug Delivery

Nanoemulsions can be surface-modified with targeting ligands such as:

- Antibodies for selective binding to cancer cell antigens.
- Peptides or aptamers targeting specific receptors.
- Folic acid or transferrin for tumor targeting.

This enhances accumulation at desired sites, minimizes off-target effects, and improves therapeutic index (Singh & Lillard, 2009).

9.3. Combination Therapies and Theranostics

Nanoemulsions enable co-delivery of multiple drugs with synergistic effects, or drugs combined with diagnostic agents for simultaneous therapy and imaging (theranostics), facilitating personalized medicine (Porter et al., 2007).

9.4. Green and Sustainable Formulations

Research is increasingly focused on:

- Using biodegradable, natural oils and surfactants derived from renewable sources.
- Employing energy-efficient preparation techniques like spontaneous emulsification.
- Minimizing solvent use and waste to reduce environmental impact (Solans & Kunieda, 2011).

Table 9: Emerging Innovations and Future Trends in Nanoemulsions

Innovation	Description	Potential Benefits	Current Status
Stimuli-responsive systems	Release triggered by pH, temperature, enzymes	Site-specific drug delivery	Experimental/early development
Targeted nanoemulsions	Surface functionalization with ligands	Enhanced specificity, reduced side effects	Preclinical and clinical trials
Combination therapies	Co-delivery of drugs or drugs + imaging agents	Synergistic therapy, theranostics	Research stage
Green formulation methods	Use of natural oils, biodegradable surfactants	Sustainability, reduced toxicity	Growing interest
Continuous manufacturing	Inline quality control and scalable processes	Industrial scale-up, cost-effectiveness	Emerging technologies

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 856-870 www.ijprajournal.com ISSN: 2456-4494

X. CONCLUSION

Nanoemulsions have emerged as a potent platform for improving the delivery of poorly water-soluble drugs by enhancing solubility, bioavailability, and therapeutic outcomes. Although challenges in stability, manufacturing scale-up, and safety profiling persist, ongoing advancements in formulation science, stimuli-responsive technologies, and targeting strategies are poised to overcome these barriers. Collaborative efforts between academia, industry, and regulatory agencies will be crucial to realizing the full clinical potential of nanoemulsion-based drug delivery.

REFERENCES

[1]. Muller, R. H., Mader, K., & Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 161–177. https://doi.org/10.1016/S0939-6411(00)00087-4

[2]. Lipinski, C. A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods, 44(1), 235–249. https://doi.org/10.1016/S1056-8719(00)00107-6

[3]. Tadros, T., Izquierdo, R., Esquena, J., & Solans, C. (2004). Formation and stability of nano-emulsions. Advances in Colloid and Interface Science, 108–109, 303–318. https://doi.org/10.1016/j.cis.2003.10.023

[4]. Solans, C., Izquierdo, P., Nolla, J., Azemar, N., & Garcia-Celma, M. J. (2005). Nano-emulsions. Current Opinion in Colloid & Interface Science, 10(3–4), 102–110. https://doi.org/10.1016/j.cocis.2005.06.004

[5]. Mason, T. G., Wilking, J. N., Meleson, K., Chang, C. B., & Graves, S. M. (2006). Nanoemulsions: Formation, structure, and physical properties. Journal of Physics: Condensed Matter, 18(41), R635–R666. https://doi.org/10.1088/0953-8984/18/41/R01

[6]. Kesisoglou, F., Panmai, S., & Wu, Y. (2007). Nanosizing—Oral formulation development and biopharmaceutical evaluation. Advanced Drug Delivery Reviews, 59(7), 631–644. https://doi.org/10.1016/j.addr.2007.05.012

[7]. Serajuddin, A. T. M. (2007). Salt formation to improve drug solubility. Advanced Drug Delivery Reviews, 59(7), 603–616. https://doi.org/10.1016/j.addr.2007.04.016

[8]. Porter, C. J., Trevaskis, N. L., & Charman, W. N. (2007). Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nature Reviews Drug Discovery, 6(3), 231–248. https://doi.org/10.1038/nrd2197

[9]. Muller, R. H., Keck, C. M., & Mehnert, W. (2011). Nanostructured lipid carriers (NLC) in cosmetic and pharmaceutical dermal products. Advanced Drug Delivery Reviews, 59(6), 522–530. https://doi.org/10.1016/j.addr.2007.05.004

[10]. Shakeel, F., Ramadan, W., Ali, B., & Shafiq, S. (2008). Nanoemulsions as vehicles for transdermal delivery of aceclofenac: Formulation and evaluation. Nanomedicine: Nanotechnology, Biology, and Medicine, 4(3), 241–247. https://doi.org/10.1016/j.nano.2008.01.002

[11]. Anton, N., Vandamme, T. F., & Vasseur, J. (2008). Design and characterization of nanoemulsions for drug delivery. Pharmaceutical Research, 25(5), 1005–1019. https://doi.org/10.1007/s11095-007-9461-9

[12]. Singh, R., & Lillard, J. W., Jr. (2009). Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology, 86(3), 215–223. https://doi.org/10.1016/j.yexmp.2009.01.004

[13]. Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2012). Drug solubility: Importance and enhancement techniques. ISRN Pharmaceutics, 2012, Article ID 195727. https://doi.org/10.5402/2012/195727

[14]. Kotta, S., Khan, A. W., Pramod, K., Ansari, S. H., & Ali, J. (2012). Exploring oral nanoemulsions for bioavailability enhancement of poorly water-soluble drugs. Expert Opinion on Drug Delivery, 9(5), 585–598. https://doi.org/10.1517/17425247.2012.672581

[15]. Lawrence, M. J., & Rees, G. D. (2012). Microemulsion-based media as novel drug delivery systems. Advanced Drug

Delivery Reviews, 64(1), 175–193. https://doi.org/10.1016/j.addr.2012.09.018

[16]. Shakeel, F., Baboota, S., Ahuja, A., Ali, J., & Shafiq, S. (2012). Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS PharmSciTech, 8(4), E104. https://doi.org/10.1208/pt0804104

[17]. Patel, P., Amiji, M., & Chaubal, M. (2011). Nanotechnology-based drug delivery systems for poor water-soluble drugs. Pharmaceutical Nanotechnology, 5(2), 75–90.

[18]. Date, A. A., Nagarsenker, M. S., & Devarajan, P. V. (2010). Oral nanoemulsions for systemic delivery of drugs: Concept, design and applications. Critical Reviews in Therapeutic Drug Carrier Systems, 27(6), 429–464. https://doi.org/10.1615/CritRevTherDrug CarrierSyst.v27.i6.30

[19]. Solans, C., & Kunieda, H. (Eds.). (2011). Industrial Applications of Microemulsions. CRC Press.

[20]. Zhang, X., Zhang, T., Ma, X., Li, W., Yang, H., & Pan, W. (2015). Physical stability and oral bioavailability of a paclitaxel nanoemulsion. International Journal of Pharmaceutics, 490(1–2), 324–331. https://doi.org/10.1016/j.ijpharm.2015.05.066

[21]. Jaiswal, M., Dudhe, R., & Sharma, P. K. (2015). Nanoemulsion: An advanced mode of drug delivery system. 3 Biotech, 5(2), 123–127. https://doi.org/10.1007/s13205-014-0191-2

[22]. Kumar, A., Ahuja, A., Ali, J., & Baboota, S. (2016). Curcumin nanoemulsion for the treatment of inflammation. Journal of Drug Targeting, 24(5), 427–434. https://doi.org/10.3109/1061186X.2015.1108328

[23]. Ganesan, P., Narayanasamy, D., & Gani, S. A. (2017). Nanoemulsion for oral delivery of Coenzyme Q10: Formulation and bioavailability evaluation. Colloids and Surfaces B: Biointerfaces, 150, 559–566. https://doi.org/10.1016/j.colsurfb.2016.11.029

[24]. Muller, R. H., & Keck, C. M. (2011). Challenges and solutions for the delivery of biotech drugs—A review of drug nanocrystal technology and lipid nanoparticles. Journal of Biotechnology, 149(1–2), 243–251. https://doi.org/10.1016/j.jbiotec.2010.11.020